The corporate reporting period has is going.
Last week, 77 companies from the S&P 500 index reported.
Today we will consider Eli Lilly. Its revenue is $11.3B. It grew by +5.1% compared to the corresponding value for the previous quarter and exceeded analysts’ expectations by +13.2%. Let’s analyze the company’s business in more detail.
Eli Lilly is a pharmaceutical company specializing in neurology, oncology, and immunology. It has offices in 120 countries. The company is a global leader in the treatment of diabetes and Alzheimer’s disease.
Eli Lilly’s revenue increased by +36.1% compared to the same quarter last year. The company spends up to 20% of its revenue on research and development of new drugs. This positions the company as a leader in one of the most challenging areas of medical research. For example, the drug Donanemab, invented in 2023, reduces the development of Alzheimer’s disease in the early stages. In addition, drugs under development, such as lebrikizumab (for atopic dermatitis) and orforgiprone (a cardiometabolic drug), have significant potential, which will also strengthen the market position.
Manufacturing costs account for 19% of the revenue structure and gross profit for 81%. Over the past quarter, the company earned a profit of $2.9B. And its market capitalization is $802B.
After the publication of the report, Eli Lilly shares gained +9.4% to reach $891 per share. In general, market participants are satisfied with the company’s current financial results and reacted positively to the forecasts for the next quarter.
*surprise – % ratio between actual and expected revenue
**growth – % ratio of the amount of revenue for the last 4 quarters compared to this value calculated for the previous quarter
